BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25081640)

  • 1. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.
    Mullen JT; Hornicek FJ; Harmon DC; Raskin KA; Chen YL; Szymonifka J; Yeap BY; Choy E; DeLaney TF; Nielsen GP
    Cancer; 2014 Dec; 120(23):3676-82. PubMed ID: 25081640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
    Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
    Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the 7th and 8th version of the AJCC classification system for soft tissue sarcomas of extremities and trunk in patients with localised, intermediate or high-grade disease treated at European tertiary sarcoma centres.
    Smolle MA; van de Sande M; Hayes A; Bergovec M; Smith HG; Liegl-Atzwanger B; Tunn PU; Niethard M; Windhager R; Szkandera J; Leithner A
    Eur J Surg Oncol; 2021 Aug; 47(8):2182-2188. PubMed ID: 33865657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival.
    Chou YS; Liu CY; Chen WM; Chen TH; Chen PC; Wu HT; Chiou HJ; Shiau CY; Wu YC; Liu CL; Chao TC; Tzeng CH; Yen CC
    J Surg Oncol; 2012 Aug; 106(2):155-61. PubMed ID: 22297812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
    Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
    Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma.
    Gannon NP; Stemm MH; King DM; Bedi M
    J Cancer Res Clin Oncol; 2019 May; 145(5):1321-1330. PubMed ID: 30847552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic Response to Neoadjuvant Therapy Is Not Predictive of Favorable Outcomes in High-grade Pleomorphic Soft Tissue Sarcoma.
    Cates JMM
    Am J Surg Pathol; 2019 Apr; 43(4):564-572. PubMed ID: 30628925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
    Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
    Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of multimodality therapy use for extremity sarcoma in the United States.
    Sherman KL; Wayne JD; Chung J; Agulnik M; Attar S; Hayes JP; Laskin WB; Peabody TD; Bentrem DJ; Pollock RE; Bilimoria KY
    J Surg Oncol; 2014 Apr; 109(5):395-404. PubMed ID: 24375444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas.
    Squires MH; Ethun CG; Suarez-Kelly LP; Yu PY; Hughes TM; Shelby RD; Tran TB; Poultsides G; Charlson J; Gamblin TC; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick BA; Fields RC; Pollock RE; Grignol V; Cardona K; Howard JH
    J Surg Res; 2020 Jan; 245():577-586. PubMed ID: 31494391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological outcome of patients with deeply located soft tissue sarcoma of the pelvis: a follow up study at minimum 5 years after diagnosis.
    Nakamura T; Abudu A; Murata H; Grimer RJ; Carter SR; Tillman RM; Jeys L
    Eur J Surg Oncol; 2013 Sep; 39(9):1030-5. PubMed ID: 23347778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.
    Weitz J; Antonescu CR; Brennan MF
    J Clin Oncol; 2003 Jul; 21(14):2719-25. PubMed ID: 12860950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma.
    Vaynrub M; Taheri N; Ahlmann ER; Yao C; Fedenko AN; Allison DC; Chawla SP; Menendez LR
    J Surg Oncol; 2015 Feb; 111(2):152-7. PubMed ID: 25175933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
    Mullen JT; Kobayashi W; Wang JJ; Harmon DC; Choy E; Hornicek FJ; Rosenberg AE; Chen YL; Spiro IJ; DeLaney TF
    Cancer; 2012 Aug; 118(15):3758-65. PubMed ID: 22180344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience.
    Raval RR; Frassica D; Thornton K; Meyer C; Ettinger DS; Frassica F; Weber K; Terezakis SA
    Am J Clin Oncol; 2017 Apr; 40(2):214-217. PubMed ID: 25268069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
    Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA
    Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radiotherapy for pediatric and young adult nonrhabdomyosarcoma soft-tissue sarcoma.
    Smith KB; Indelicato DJ; Knapik JA; Lagmay JP; Morris C; Kirwan JM; Zlotecki RA; Scarborough MT; Gibbs CP; Marcus RB
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):150-7. PubMed ID: 21550181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
    Eilber FC; Rosen G; Eckardt J; Forscher C; Nelson SD; Selch M; Dorey F; Eilber FR
    J Clin Oncol; 2001 Jul; 19(13):3203-9. PubMed ID: 11432887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative.
    Zaidi MY; Ethun CG; Tran TB; Poultsides G; Grignol VP; Howard JH; Bedi M; Mogal H; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick B; Fields RC; Oskouei S; Reimer N; Monson D; Maithel SK; Cardona K
    Ann Surg Oncol; 2019 Oct; 26(11):3542-3549. PubMed ID: 31342400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative radiotherapy with concomitant chemotherapy in extremity soft tissue sarcomas: long-term results of a single center.
    Yilmaz U; Kamer S; Kaya H; Sabah D; Sanli UA; Tamsel I; Yaman B; Akalin T; Anacak Y
    Strahlenther Onkol; 2023 Jun; 199(6):585-594. PubMed ID: 36725697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.